Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis

Journal of Translational Medicine

Research

Enrico Fainardi¹  Dario Di Luca²  Roberta Rizzo²  Daria Bortolotti²  Enrico Granieri³  Ilaria Casetta³  Massimiliano Castellazzi³  Silvia Pietrobon⁴  Elisa Mazzoni⁴  Fernanda Martini⁴  Mauro Tognon⁴ 

[1] Neuroradiology Unit, Department of Neurosciences, University Hospital of Ferrara, Ferrara, Italy;Section of Microbiology and Medical Genetics, Department of Medical Sciences, University of Ferrara, Via Luigi Borsari, 46, 44121, Ferrara, Italy;Section of Neurology, School of Medicine, Department of Biomedical Sciences and Specialized Surgeries, University of Ferrara, Ferrara, Italy;Section of Pathology, Oncology and Experimental Biology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara, 44121, Ferrara, Italy;

关键词: SV40;    HLA-G;    Multiple sclerosis;   

DOI  :  10.1186/s12967-016-0981-y

 received in 2016-03-29, accepted in 2016-07-13,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundMany investigators detected the simian polyomavirus SV40 footprints in human brain tumors and neurologic diseases and recently it has been indicated that SV40 seems to be associated with multiple sclerosis (MS) disease. Interestingly, SV40 interacts with human leukocyte antigen (HLA) class I molecules for cell entry. HLA class I antigens, in particular non-classical HLA-G molecules, characterized by an immune-regulatory function, are involved in MS disease, and the levels of these molecules are modified according with the disease status.ObjectiveWe investigated in serum samples, from Italian patients affected by MS, other inflammatory diseases (OIND), non-inflammatory neurological diseases (NIND) and healthy subjects (HS), SV40-antibody and soluble sHLA-G and the association between SV40-prevalence and sHLA-G levels.MethodsELISA tests were used for SV40-antibodies detection and sHLA-G quantitation in serum samples.ResultsThe presence of SV40 antibodies was observed in 6 % of patients affected by MS (N = 4/63), 10 % of OIND (N = 8/77) and 15 % of NIND (N = 9/59), which is suggestive of a lower prevalence in respect to HS (22 %, N = 18/83). MS patients are characterized by higher sHLA-G serum levels (13.9 ± 0.9 ng/ml; mean ± St. Error) in comparison with OIND (6.7 ± 0.8 ng/ml), NIND (2.9 ± 0.4 ng/ml) and HS (2.6 ± 0.7 ng/ml) subjects. Interestingly, we observed an inverse correlation between SV40 antibody prevalence and sHLA-G serum levels in MS patients.ConclusionThe data obtained showed a low prevalence of SV40 antibodies in MS patients. These results seems to be due to a generalized status of inability to counteract SV40 infection via antibody production. In particular, we hypothesize that SV40 immune-inhibitory direct effect and the presence of high levels of the immune-inhibitory HLA-G molecules could co-operate in impairing B lymphocyte activation towards SV40 specific peptides.

【 授权许可】

CC BY   
© The Author(s) 2016